Predictive Value of Pretreatment Neutrophil to Albumin Ratio in Response to Neoadjuvant Chemotherapy of Breast Cancer

References

• Sung H, Ferlay J, Siegel RL. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from national surgical adjuvant breast and bowel project B-18. J Clin Oncol. 1997;15(7):2483–2493. doi:10.1200/JCO.1997.15.7.2483
   PubMed Web of Science ®Google Scholar
• Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–172. doi:10.1016/S0140-6736(13)62422-8
   PubMed Web of Science ®Google Scholar
• Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26(8):1275–1281. doi:10.1200/JCO.2007.14.4147
   PubMed Web of Science ®Google Scholar
• Guo L, Kong D, Liu J, et al. Breast cancer heterogeneity and its implication in personalized precision therapy. Exp Hematol Oncol. 2023;12(1):3. doi:10.1186/s40164-022-00363-1
   PubMedGoogle Scholar
• Mantovani A. Cancer: inflaming metastasis. Nature. 2009;457(7225):36–37. doi:10.1038/457036b
   PubMed Web of Science ®Google Scholar
• Wiseman MJ. Nutrition and cancer: prevention and survival. Br J Nutr. 2019;122(5):481–487. doi:10.1017/S0007114518002222
   PubMed Web of Science ®Google Scholar
• Fernandes JV, Cobucci RN, Jatoba CA, et al. The role of the mediators of inflammation in cancer development. Pathol Oncol Res. 2015;21(3):527–534. doi:10.1007/s12253-015-9913-z
   PubMed Web of Science ®Google Scholar
• Chen L, Bai P, Kong X, et al. Prognostic nutritional index (PNI) in patients with breast cancer treated with neoadjuvant chemotherapy as a useful prognostic indicator. Front Cell Dev Biol. 2021;9:656741. doi:10.3389/fcell.2021.656741
   PubMed Web of Science ®Google Scholar
• Ethier JL, Desautels D, Templeton A, Shah PS, Amir E. Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. Breast Cancer Res. 2017;19(1):2.
   PubMed Web of Science ®Google Scholar
• Jiang C, Lu Y, Zhang S, Huang Y. systemic immune-inflammation index is superior to neutrophil to lymphocyte ratio in prognostic assessment of breast cancer patients undergoing neoadjuvant chemotherapy. Biomed Res Int. 2020;2020:7961568. doi:10.1155/2020/7961568
   PubMed Web of Science ®Google Scholar
• Lis CG, Grutsch JF, Vashi PG, Lammersfeld CA. Is serum albumin an independent predictor of survival in patients with breast cancer? JPEN J Parenter Enteral Nutr. 2003;27(1):10–15. doi:10.1177/014860710302700110
   PubMed Web of Science ®Google Scholar
• Boonpipattanapong T, Chewatanakornkul S. Preoperative carcinoembryonic antigen and albumin in predicting survival in patients with colon and rectal carcinomas. J Clin Gastroenterol. 2006;40(7):592–595. doi:10.1097/00004836-200608000-00006
   PubMed Web of Science ®Google Scholar
• Onate-Ocana LF, Aiello-Crocifoglio V, Gallardo-Rincon D, et al. Serum albumin as a significant prognostic factor for patients with gastric carcinoma. Ann Surg Oncol. 2007;14(2):381–389. doi:10.1245/s10434-006-9093-x
   PubMed Web of Science ®Google Scholar
• Feng C, Yu H, Lei H, et al. A prognostic model using the neutrophil-albumin ratio and PG-SGA to predict overall survival in advanced palliative lung cancer. BMC Palliat Care. 2022;21(1):81. doi:10.1186/s12904-022-00972-x
   PubMedGoogle Scholar
• Yu YY, Lin YT, Chuang HC, et al. Prognostic utility of neutrophil-to-albumin ratio in surgically treated oral squamous cell carcinoma. Head Neck. 2023;45(11):2839–2850. doi:10.1002/hed.27511
   PubMedGoogle Scholar
• Varim C, Celik FD, Sunu C, et al. The role of neutrophil albumin ratio in predicting the stage of non-small cell lung cancer. Eur Rev Med Pharmacol Sci. 2022;26(8):2900–2905. doi:10.26355/eurrev_202204_28621
   PubMed Web of Science ®Google Scholar
• Li R, Sun Z, Song S, et al. NARFIB: a novel prognostic score based on the neutrophil-to-albumin ratio and fibrinogen can predict the prognosis of gastrointestinal stromal tumors. Cancer Manag Res. 2020;12:11183–11190. doi:10.2147/CMAR.S281375
   PubMed Web of Science ®Google Scholar
• Tawfik B, Mokdad AA, Patel PM, Li HC, Huerta S. The neutrophil to albumin ratio as a predictor of pathological complete response in rectal cancer patients following neoadjuvant chemoradiation. Anticancer Drugs. 2016;27(9):879–883. doi:10.1097/CAD.0000000000000411
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond M, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline focused update. J Clin Oncol. 2018;36(20):2105–2122. doi:10.1200/JCO.2018.77.8738
   PubMed Web of Science ®Google Scholar
• Pennisi A, Kieber-Emmons T, Makhoul I, Hutchins L. Relevance of pathological complete response after neoadjuvant therapy for breast cancer. Breast Cancer. 2016;10:103–106. doi:10.4137/BCBCR.S33163
   PubMedGoogle Scholar
• Patel PM, Harris K, Huerta S. Clinical and molecular diagnosis of pathologic complete response in rectal cancer. Expert Rev Mol Diagn. 2015;15(11):1505–1516. doi:10.1586/14737159.2015.1091728
   PubMed Web of Science ®Google Scholar
• Ramzan Z, Nassri AB, Huerta S. Genotypic characteristics of resistant tumors to pre-operative ionizing radiation in rectal cancer. World J Gastrointest Oncol. 2014;6(7):194–210. doi:10.4251/wjgo.v6.i7.194
   PubMed Web of Science ®Google Scholar
• Davola ME, Cormier O, Vito A, et al. Oncolytic BHV-1 is sufficient to induce immunogenic cell death and synergizes with low-dose chemotherapy to dampen immunosuppressive T regulatory cells. Cancers. 2023;15(4):1295. doi:10.3390/cancers15041295
   PubMedGoogle Scholar
• Marchetti C, D’Indinosante M, Bottoni C, et al. NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer. Sci Rep. 2021;11(1):11125. doi:10.1038/s41598-021-90361-w
   PubMed Web of Science ®Google Scholar
• Xie H, Ruan G, Ge Y, et al. Inflammatory burden as a prognostic biomarker for cancer. Clin Nutr. 2022;41(6):1236–1243. doi:10.1016/j.clnu.2022.04.019
   PubMed Web of Science ®Google Scholar
• Fornarini G, Rebuzzi SE, Buti S, et al. A novel immunotherapy prognostic score for patients with pretreated advanced urInary TrAct CArcinoma from the subgroup analysis of the SAUL study: the ITACA score. Minerva Urol Nephrol. 2023;75(3):308–318. doi:10.23736/S2724-6051.22.05135-7
   PubMedGoogle Scholar
• Zhang CL, Gao MQ, Jiang XC, et al. Research progress and value of albumin-related inflammatory markers in the prognosis of non-small cell lung cancer: a review of clinical evidence. Ann Med. 2023;55(1):1294–1307. doi:10.1080/07853890.2023.2192047
   PubMed Web of Science ®Google Scholar
• Konecny AJ, Mage P, Tyznik AJ, Prlic M, Mair F. 50-color phenotyping of the human immune system with in-depth assessment of T cells and dendritic cells. bioRxiv. 2023. doi:10.1101/2023.12.14.571745
   Google Scholar
• Zhang X, Hu M, Li S, et al. Clinical study on Yanghe decoction in improving neo-adjuvant chemotherapy efficacy and immune function of breast cancer patients. Medicine. 2022;101(10):e29031. doi:10.1097/MD.0000000000029031
   PubMed Web of Science ®Google Scholar
• Jiang C, Xiu Y, Yu X, et al. Prognostic value of a modified systemic inflammation score in breast cancer patients who underwent neoadjuvant chemotherapy. BMC Cancer. 2022;22(1):1249. doi:10.1186/s12885-022-10291-2
   PubMedGoogle Scholar
• Mishalian I, Bayuh R, Levy L, et al. Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties during tumor progression. Cancer Immunol Immunother. 2013;62(11):1745–1756. doi:10.1007/s00262-013-1476-9
   PubMed Web of Science ®Google Scholar
• Chen HC, Eling N, Martinez-Jimenez CP, et al. IL-7-dependent compositional changes within the gammadelta T cell pool in lymph nodes during ageing lead to an unbalanced anti-tumour response. EMBO Rep. 2019;20(8):e47379. doi:10.15252/embr.201847379
   PubMedGoogle Scholar
• Mensurado S, Rei M, Lanca T, et al. Tumor-associated neutrophils suppress pro-tumoral IL-17+ gammadelta T cells through induction of oxidative stress. PLoS Biol. 2018;16(5):e2004990. doi:10.1371/journal.pbio.2004990
   PubMedGoogle Scholar